Ticker Launch
Sign inTry it free

SPAC · Merger completed

European Biotech Acquisition Corp.

Business combination with Oculis Holding AG

European Biotech Acquisition Corp. is a blank-check company (SPAC) that raised $120M in its initial public offering on Mar 17, 2021, listing on Nasdaq Capital Market. It completed its business combination with Oculis Holding AG on Mar 8, 2023; the combined company is Oculis Holding AG (OCS). Davis Polk advised the SPAC and A&O Shearman advised the underwriters on the IPO.

Oculis Holding AG is a global biopharmaceutical company focused on eye care, aiming to save sight and address medical needs in ophthalmology through new treatments.

Status
Merger completed
IPO date
Mar 17, 2021
IPO size
$120M
IPO exchange
Nasdaq Capital Market
Target
Oculis Holding AG (Oculis)
Announced
Oct 17, 2022
Closed
Mar 8, 2023
Combined company
Oculis Holding AG (OCS)
SPAC counsel (IPO)
Davis Polk and Maples and Calder
Underwriters' counsel (IPO)
A&O Shearman

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2023